بررسی تاثیر داروی سیلوستازول بر نتایج حاصل از آنژیوپلاستی شریانی زیر زانو در بیماران با ایسکمی اندام تحتانی

[1] Dorros G, Jaff MR, Dorros AM, Mathiak LM, He T. Tibioperoneal
(outflow lesion) angioplasty can be used as primary treatment
in 235 patients with critical limb ischemia: Five-year
follow-up. Circulation 2001; 104(17):2057-62. [DOI:10.1161/
hc4201.097943] [PMID]
[2] Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF,
et al. BASIL trial participants. Bypass versus angioplasty in severe
ischemia of the leg (BASIL): Multicentre, randomized controlled
trial. Lancet. 2005; 366(9501):1925-34. [DOI:10.1016/
S0140-6736(05)67704-5]
[3] Söderström MI, Arvela EM, Korhonen M, Halmesmäki KH, Albäck
AN, Biancari F, et al. Infrapopliteal percutaneous transluminal
angioplasty versus bypass surgery as first-line strategies
in critical leg ischemia: A propensity score analysis. Ann Surg.
2010; 252(5):765-73. [DOI:10.1097/SLA.0b013e3181fc3c73]
[PMID]
[4] Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA,
Fowkes FG, et al. Inter-society consensus for the management
of peripheral arterial disease (TASC II). Eur J Vasc Endovasc
Surg. 2007; 33(S 1):S1-75. [DOI:10.1016/j.ejvs.2006.09.024]
[PMID]
[5] Baumann F, Willenberg T, Do DD, Keo HH, Baumgartner I, Diehm
N. Endovascular revascularization of below-the-knee arteries:
Prospective short-term angiographic and clinical followup.
J Vasc Interv Radiol. 2011; 22(12):1665-73. [DOI:10.1016/j.
jvir.2011.08.028] [PMID]
[6] Schmidt A, Ulrich M, Winkler B, Klaeffling C, Bausback Y,
Bräunlich S, et al. Angiographic patency and clinical outcome
after balloon-angioplasty for extensive infrapopliteal arterial
disease. Catheter Cardiovasc Interv. 2010; 76(7):1047-54.
[DOI:10.1002/ccd.22658] [PMID]
[7] Iida O, Soga Y, Kawasaki D, Hirano K, Yamaoka T, Suzuki K, et
al. Angiographic restenosis and its clinical impact after infrapopliteal
angioplasty. Eur J Vasc Endovasc Surg. 2012; 44(4):425-
31. [DOI:10.1016/j.ejvs.2012.07.017] [PMID]
[8] Bosiers M, Scheinert D, Peeters P, Torsello G, Zeller T, Deloose
K, et al. Randomized comparison of everolimus-eluting versus
bare-metal stents in patients with critical limb ischemia and
infrapopliteal arterial occlusive disease. J Vasc Surg. 2012;
55(2):390-8. [DOI:10.1016/j.jvs.2011.07.099] [PMID]
[9] Scheinert D, Ulrich M, Scheinert S, Sax J, Bräunlich S, Biamino
G. Comparison of sirolimus-eluting vs. bare-metal stents for
the treatment of infrapopliteal obstructions. EuroIntervention.
2006; 2(2):169-74. [PMID]
[10] Schmidt A, Piorkowski M, Werner M, Ulrich M, Bausback Y,
Bräunlich S, et al. First experience with drug-eluting balloons
in infrapopliteal arteries: Restenosis rate and clinical outcome.
J Am Coll Cardiol. 2011; 58(11):1105-9. [DOI:10.1016/j.
jacc.2011.05.034] [PMID]
[11] Soga Y, Mii S, Aihara H, Okazaki J, Kuma S, Yamaoka T, et
al. Comparison of clinical outcome after bypass surgery vs.
endovascular therapy for infrainguinal artery disease in patients
with critical limb ischemia. Circ J. 2013; 77(8):2102-9.
[DOI:10.1253/circj.CJ-13-0020] [PMID]
[12] Iida O, Nakamura M, Yamauchi Y, Fukunaga M, Yokoi Y, Yokoi
H, et al. 3-Year outcomes of the OLIVE registry, a prospective
multicenter study of patients with critical limb ischemia: A prospective,
multi-center, three-year follow-up study on endovascular
treatment for infra-inguinal vessel in patients with critical
limb ischemia. JACC Cardiovasc Interv. 2015; 8(11):1493-502.
[DOI:10.1016/j.jcin.2015.07.005] [PMID]
[13] Soga Y, Iida O, Hirano K, Suzuki K, Kawasaki D, Miyashita Y,
et al. Impact of cilostazol after endovascular treatment for infrainguinal
disease in patients with critical limb ischemia. J Vasc
Surg. 2011; 54(6):1659-67. [DOI:10.1016/j.jvs.2011.06.024]
[PMID]
[14] Soga Y, Iida O, Kawasaki D, Hirano K, Yamaoka T, Suzuki K.
Impact of Cilostazol on Angiographic Restenosis after Balloon
Angioplasty for Infrapopliteal Artery Disease in Patients
with Critical Limb Ischemia. Eur J Vasc Endovasc Surg. 2012;
44(6):577-81. [DOI:10.1016/j.ejvs.2012.09.020] [PMID]
[15] Setacci C, Ricco JB, European Society for Vascular Surgery.
Guidelines for critical limb ischaemia and diabetic footeintroduction.
Eur J Vasc Endovasc Surg. 2011; 42(S 2):S1-3.
[DOI:10.1016/S1078-5884(11)00715-5]
[16] Iida O, Nanto S, Uematsu M, Morozumi T, Kitakaze M, Nagata
S. Cilostazol reduces restenosis after endovascular therapy
in patients with femoropopliteal lesions. J Vasc Surg. 2008;
48(1):144-9. [DOI:10.1016/j.jvs.2008.02.062] [PMID]
[17] Soga Y, Yokoi H, Kawasaki T, Nakashima H, Tsurugida M, Hikichi
Y, et al. Efficacy of cilostazol after endovascular therapy
for femoropopliteal artery disease in patients with intermittent
claudication. J Am Coll Cardiol. 2009; 53(1):48-53.
[DOI:10.1016/j.jacc.2008.09.020] [PMID]
[18] Kimura T, Nosaka H, Yokoi H, Iwabuchi M, Nobuyoshi M. Serial
angiographic follow-up after Palmaz-Schatz stent implantation:
Comparison with conventional balloon angioplasty.
J Am Coll Cardiol. 1993; 21(7):1557-63. [DOI:10.1016/0735-
1097(93)90368-B]
[19] Kimura T, Yokoi H, Nakagawa Y, Tamura T, Kaburagi S, Sawada
Y, et al. Threeyear follow-up after implantation of metallic
coronary-artery stents. N Engl J Med. 1996; 334(9):561-6.
[DOI:10.1056/NEJM199602293340903] [PMID]
[20] Soga Y, Takahara M, Iida O, Yamauchi Y, Hirano K, Fukunaga
M, et al. Efficacy of cilostazol for below-the-knee artery disease
after balloon angioplasty in patients with severe limb
ischemia (CABBAGE Trial). Ann Vasc Surg. 2017; 45:22-8.
[DOI:10.1016/j.avsg.2017.05.029] [PMID]
[21] Iida O, Yokoi H, Soga Y, Inoue N, Suzuki K, Yokoi Y, et al.
Cilostazol reduces angiographic restenosis after endovascular
therapy for femoropopliteal lesions in the Sufficient Treatment
of Peripheral Intervention by Cilostazol study. Circulation.
2013; 127(23):2307-15. [DOI:10.1161/CIRCULATIONAHA.
112.000711] [PMID]